Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Medical application of Harpagoside ingredient

A technology of use and pharmacy, which is applied in the field of medical use of harpagoside compounds, and can solve unseen problems and the like

Active Publication Date: 2011-11-23
CHINA PHARM UNIV
View PDF0 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Harpagoside is its index component (see European Pharmacopoeia 6th edition), which has pharmacological activities such as anti-inflammation and analgesia, but there are no reports of its activities related to insulin resistance and metabolic syndrome.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medical application of Harpagoside ingredient
  • Medical application of Harpagoside ingredient
  • Medical application of Harpagoside ingredient

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0028] Hypoglycemic experiment in normal mice

[0029] experimental method:

[0030] 90 healthy mice were randomly divided into 9 groups according to body weight, 10 in each group. The 7 groups of administration groups were given harpagoside 5mg / kg, harpagoside 10mg / kg, harpagoside 5mg / kg, harpagoside 10mg / kg, 8-cinnamoyl predjoside 5mg / kg, 8-O-trans Formula-p-hydroxycinnamoyl harpaside 5mg / kg, 8-O-trans-p-hydroxycinnamoyl harpaside 10mg / kg, the control group was given the same amount of normal saline, and the positive drug group was given metformin 140mg / kg, administered by intragastric administration , once a day, for 7 days in a row. Fasting for 2 hours before the last administration (without water), and measuring fasting blood glucose (FBG) 1 hour after administration.

[0031] Experimental results:

[0032] Table 1 hypoglycemic effect on normal mice ( n=10)

[0033]

[0034] * Indicates that the administration group and the positive drug group are significantly ...

Embodiment 2

[0037] Hypoglycemic experiment in acute insulin resistant mice:

[0038] experimental method:

[0039] 1. Prepare the supernatant of activated macrophages. Experiments were carried out after mice were adaptively fed for one week (body weight was about 25 g). Mice were killed by dislocation, macrophages were prepared, stimulated with LPS (2 μg / ml), and the supernatant was collected 48 hours later. TNF-a and IL-6 were measured by ELISA, and the contents of the two inflammatory cytokines were significantly higher than those in the control group, indicating that the stimulation was successful, and they were stored at -70°C for later use.

[0040] 2 Preparation of inflammatory insulin resistance model. The mice were fasted for 12 hours, administered by intragastric administration, and 30 minutes later, 200 μl of the supernatant of activated macrophages was injected intraperitoneally (diluted according to a certain ratio). After 1 hour, glucose (4 g / kg) was given by intragastric...

Embodiment 3

[0048] 3T3-L1 adipocyte sugar uptake experiment

[0049] experimental method:

[0050] a) 3T3-L1 preadipocyte culture

[0051] 3T3-L1 preadipocytes were placed in DMEM medium (containing 0.1 g / L streptomycin and 100 U / ml penicillin) with 10% neonatal calf serum at 37°C, 5% CO 2 , cultured under saturated humidity conditions. Cells in the logarithmic growth phase were used for experiments.

[0052] b) Effect on the viability of 3T3-L1 preadipocytes

[0053] Take 4×10 4 Cells / ml 180μl were seeded in 96-well plate, 37℃, 5%CO 2 , cultured under saturated humidity conditions. When the cell density reached about 85%, different concentrations of the test drug were added for 48 hours. The supernatant was discarded, and 180 μl of serum-free DMEM and 20 μl of MTT (5 mg / ml) were added to each well to continue culturing at 37° C. for 4 h. Then carefully discard the supernatant, add 150 μl DMSO to each well and shake for 10 min, measure the absorbance at 570 nm, and calculate the c...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the field of natural medicaments, in particular to a medical application of Harpagoside compound, i.e. the pharmacological effect of Harpagoside compound can be applied to treating metabolic diseases caused by insulin resistance or glycometabolism disorder complication caused by insulin resistance.

Description

technical field [0001] The invention relates to the field of natural medicines, in particular to the medical application of harpagoside compounds. Background technique [0002] Metabolic Syndrome (MS) is a combination of central obesity, diabetes or impaired glucose regulation, hypertension, dyslipidemia and other metabolic diseases caused by insulin resistance (Insulin Resistance, IR). Group of clinical syndromes. In 1997, Zemmet believed that the common pathological basis of the above-mentioned metabolic diseases was the disorder of sugar and fat metabolism caused by insulin resistance, so he proposed to collectively call it "metabolic syndrome". In 1999, the World Health Organization (WHO) officially recognized the nomenclature and put forward a comprehensive discussion. According to the standard diagnosis of MS in China recommended by IDF, the prevalence rate of MS is 16.5%. This result suggests that the number of adults with MS aged 35-74 in my country has risen to 77...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/7048A61P3/00A61P3/10A61P3/06A61P9/12A61P27/02A61P27/12A61P9/10A61P9/14A61P13/12A61P25/28
Inventor 戚进宋晓晨余伯阳朱丹妮寇俊萍
Owner CHINA PHARM UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com